Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years

Luca Mastorino,1 Paolo Dapavo,1 Martina Burlando,2 Paolo Gisondi,3 Carlo Alberto Maronese,4,5 Angelo Ruggiero,6 Marco Galluzzo,7,8 Maria Carla Pisani,9 Lidia Sacchelli,10 Giacomo Caldarola,11 Gianluca Avallone,1,4 Angelo Valerio Marzano,4,5 Matteo Megna,6 Elena Campione,7,8 Francesco Loconsole,9 Fed...

Full description

Saved in:
Bibliographic Details
Main Authors: Mastorino L, Dapavo P, Burlando M, Gisondi P, Maronese CA, Ruggiero A, Galluzzo M, Pisani MC, Sacchelli L, Caldarola G, Avallone G, Marzano AV, Megna M, Campione E, Loconsole F, Bardazzi F, De Simone C, Quaglino P, Ribero S
Format: Article
Language:English
Published: Dove Medical Press 2025-08-01
Series:Psoriasis: Targets and Therapy
Subjects:
psoriasis
tildrakizumab
elderly
safety
real-life
Online Access:https://www.dovepress.com/effectiveness-and-safety-of-tildrakizumab-in-elderly-and-frail-elderly-peer-reviewed-fulltext-article-PTT
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/effectiveness-and-safety-of-tildrakizumab-in-elderly-and-frail-elderly-peer-reviewed-fulltext-article-PTT

Similar Items